The PMCB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PMCB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PMCB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PMCB Detailed Price Forecast - CNN Money||View PMCB Detailed Summary - Google Finance|
|View PMCB Detailed Summary - Yahoo! Finance||View PMCB Stock Research & Analysis - Zacks.com|
|View PMCB Trends & Analysis - Trade-Ideas||View PMCB Major Holders - Barrons|
|View PMCB Call Transcripts - NASDAQ||View PMCB Breaking News & Analysis - Seeking Alpha|
|View PMCB Annual Report - CompanySpotlight.com||View PMCB OTC Short Report - OTCShortReport.com|
|View PMCB Fundamentals - TradeKing||View PMCB SEC Filings - Bar Chart|
|View Historical Prices for PMCB - The WSJ||View Performance/Total Return for PMCB - Morningstar|
|View the Analyst Estimates for PMCB - MarketWatch||View the Earnings History for PMCB - CNBC|
|View the PMCB Earnings - StockMarketWatch||View PMCB Buy or Sell Recommendations - MacroAxis|
|View the PMCB Bullish Patterns - American Bulls||View PMCB Short Pain Metrics - ShortPainBot.com|
|View PMCB Stock Mentions - StockTwits||View PMCB Stock Mentions - PennyStockTweets|
|View PMCB Stock Mentions - Twitter||View PMCB Investment Forum News - Investor Hub|
|View PMCB Stock Mentions - Yahoo! Message Board||View PMCB Stock Mentions - Seeking Alpha|
|View Insider Transactions for PMCB - SECform4.com||View Insider Transactions for PMCB - Insider Cow|
|View PMCB Major Holdings Summary - CNBC||View Insider Disclosure for PMCB - OTC Markets|
|View Insider Transactions for PMCB - Yahoo! Finance||View Institutional Holdings for PMCB - NASDAQ|
|View PMCB Stock Insight & Charts - FinViz.com||View PMCB Investment Charts - StockCharts.com|
|View PMCB Stock Overview & Charts - BarChart||View PMCB User Generated Charts - Trading View|
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
Posted on Monday February 04, 2019
Clinical stage biotechnology company PharmaCyte Biotech (PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for its development of a treatment for patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). PharmaCyte is a California-based biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®. When the company recently announced that it had successfully encapsulated the live cells used in its therapy for patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC), and that those cells are now growing and dividing inside the Cell-in-a-Box® capsules, the news seemed to suggest that all of the pieces necessary to complete and submit the long overdue IND application to the FDA are falling into place for the company’s upcoming clinical trial in the treatment of LAPC.
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
Posted on Wednesday January 23, 2019
With PharmaCyte Biotech, Inc.’s (PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct its clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), and with the recent news that the live cells necessary for that clinical trial have been encapsulated and are growing, we decided to reach out to world-renowned clinician and oncologist, Dr. Manuel Hidalgo, to discuss his role as the Principal Investigator of PharmaCyte’s upcoming clinical trial, the company’s technology, the trial design and more. Dr. Hidalgo is a Professor of Medicine at the Harvard Medical School. He is also the Chief of the Division of Hematology Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center (BIDMC). Dr. Hidalgo is also Deputy Associate Director for Clinical Sciences at the Dana Farber Harvard Cancer Center.
PharmaCyte Biotech Releases CEO Interview from The Big Biz Show
Posted on Tuesday January 22, 2019
PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has added a new CEO interview to the company’s website. Chief Executive Officer, Kenneth L. Waggoner, was featured on “The Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio program, on Friday, January 18th.
PharmaCyte Biotech’s CEO Interviewing Live on The Big Biz Show
Posted on Thursday January 17, 2019
PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its Chief Executive Officer, Kenneth L. Waggoner, will be featured in a live interview on “The Big Biz Show,” an Emmy Award-winning nationally syndicated radio and TV program, on Friday, January 18th.